Method for Scalp Cooling Now Offered to More Patients – Reduces Hair Loss in Cancer Patients
11.11.2024 08:00:00 CET | Aleris | Press Release
The Aleris Oncology Clinic at Sabbatsberg Hospital, Stockholm, Sweden is expanding access to an innovative scalp cooling treatment for cancer patients after a successful pilot project in collaboration with Dignitana.

— We have observed improvements in our patients’ psychosocial well-being, says Anna-Maria Hasselgren Häll, oncology nurse at Aleris Christinakliniken.
Aleris has conducted a series of extensive trials on an innovative scalp cooling treatment that reduces hair loss in cancer patients undergoing chemotherapy for solid tumors. Patients beginning chemotherapy will now be offered the option to use scalp cooling.
— Being able to retain hair during cancer treatment is not just about appearance. Patients often express how important it is to keep their hair for self-esteem and everyday life, says Anna-Maria Hasselgren Häll.
By lowering the temperature in the scalp, blood flow and metabolism are reduced, causing hair follicles to absorb less of the chemotherapy drugs. This allows patients to retain their hair to a greater extent during challenging treatments, which significantly enhances their quality of life and well-being.
The scalp cooling treatment was developed by the medical technology company Dignitana. A personalized cap is connected to the DigniCap Delta machine, which cools the patient’s scalp during chemotherapy. This has proven to be highly effective in reducing hair loss.
— We have a close collaboration with Aleris Christinakliniken, which was quick to recognize the value of this treatment for their patients. I am very pleased that they are now taking this forward, giving as many people as possible the chance to preserve their hair and feel better, says Fredrik Jonsson, CEO of Dignitana.
Aleris Christinakliniken has now chosen to permanently offer Dignitana’s DigniCap Delta to meet demand and enhance the quality of cancer care. Aleris expects that this initiative will enable more cancer patients to receive support in connection with their chemotherapy. There is significant demand for this treatment, with patients from across Sweden reaching out directly to the clinic or Dignitana.
— We often receive calls from patients wanting to know where they can access scalp cooling treatment. It is therefore very gratifying that Aleris Christinakliniken wants to make this treatment more widely available. In the long term, scalp cooling should be an integrated part of modern cancer care, says Fredrik Jonsson at Dignitana.
Every year, approximately 72,000 people in Sweden are diagnosed with cancer, of which over 8,000 are breast cancer cases [1]. The number of cancer cases in Sweden has increased over the last fifty years, although mortality has decreased during the same period. This is largely due to advances in research, improved early detection, better treatment options, and lifestyle changes.
For more information, contact
Anna-Maria Hasselgren Häll, Licensed Oncology Nurse and Head of Unit at Aleris Christinakliniken, +46 730 38 38 20 (press service), anna-maria.hasselgren-hall@aleris.se
Fredrik Jonsson, CEO of Dignitana AB (publ), +46 708 76 64 44, fredrik.jonsson@dignitana.com
About Aleris Christinakliniken
The Aleris Oncology Clinic specializes in cancer care, focusing on breast diagnostics, treatment, and follow-up of breast cancer. Our team includes a professor, an associate professor, and several oncology specialists, and at the clinic, you’ll meet our oncology nurses with specialist knowledge in cancer care.
About Dignitana
Dignitana is a medical technology company based in Lund, Sweden, specializing in scalp cooling as a method for cancer patients to minimize hair loss during chemotherapy. Founded in 1996 by oncology nurse Yvonne Olofsson, Dignitana has been internationally acclaimed as a life-changing medical advancement for cancer patients.
Keywords
Contacts
Kenan Harbas
Tel:+46 70-783 42 03Kenan.Harbas@aleris.seImages
Links
Alternative languages
Subscribe to releases from Aleris
Subscribe to all the latest releases from Aleris by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Aleris
Vårdgarantiutredningen blev en tummetott17.6.2026 14:22:14 CEST | Pressmeddelande
Köerna är den svenska sjukvårdens eviga problem. I dag presenterades den statliga utredningen om hur väntetiderna ska kortas. Utredningen innehåller flera välkomna förslag, men går inte tillräckligt långt för att ge patienter de rättigheter som krävs för att få vård i tid.
Ny bok ska hjälpa vårdpersonal med svåra samtal27.5.2026 06:45:00 CEST | Pressmeddelande
Frågor om mening, hopp och livskris får allt större utrymme i samhällsdebatten och nu även i regeringens folkhälsoarbete. Samtidigt saknar många inom hälso- och sjukvård konkreta verktyg för att möta patienter i existentiella frågor. Nu lanseras en ny handbok som ska hjälpa vårdpersonal att ta de svåra samtalen i vardagen.
Hon blir ny vice ordförande i Stockholms Handelskammare21.5.2026 07:51:31 CEST | Pressmeddelande
Sofia Palmquist, vd och koncernchef för Aleris, har valts in som ny vice ordförande i Stockholms Handelskammare efter att ha varit ledamot i Handelskammarens styrelse under flera år.
Finska vårdgivaren Mehiläinen förvärvar Aleris – stärker sin närvaro i Sverige18.5.2026 08:00:15 CEST | Pressmeddelande
Den finska vårdgivaren Mehiläinen Group har signerat avtal om att förvärva Aleris. Genom förvärvet kompletterar Mehiläinen sin befintliga verksamhet i Sverige och etablerar sig i nya länder genom Aleris verksamheter i Norge och Danmark. Tillsammans genomför vårdaktörerna över 11 miljoner läkarbesök varje år och stärker sin förmåga att stödja hälso- och sjukvården i de nordiska länderna samt förbättra människors tillgång till vård.
Helseaktøren Mehiläinen kjøper Aleris18.5.2026 08:00:15 CEST | Pressmeddelande
Den finske helseaktøren Mehiläinen Group har inngått avtale om å kjøpe Aleris – og etablerer seg med det i Norge og Danmark, samt kompletterer sin virksomhet i Sverige. Sammen vil helseaktørene totalt sett ha mer enn 11 millioner legebesøk årlig, avlaste den offentlige helsetjenesten og betydelig styrke folks tilgang til helsetjenester av høy kvalitet.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom

